Showing results (221-230 of 238) with videos related to

Sort By:
Pageof 24
The New England Journal of Medicine|October 10, 1996
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study TeamD A Katzenstein, S M Hammer, M D Hughes, et al.
American Journal of Physiology. Heart and Circulatory Physiology|November 22, 2000
Enhanced cAMP-induced nitric oxide-dependent coronary dilation during myocardial stunning in conscious pigsR K Kudej, X P Zhang, B Ghaleh, et al.
The Journal of Infectious Diseases|July 1, 1995
Human immunodeficiency virus (HIV) type 1 infection status and in vitro susceptibility to HIV infection among high-risk HIV-1-seronegative hemophiliacsM M Lederman, J B Jackson, B L Kroner, et al.
The New England Journal of Medicine|May 22, 1997
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials GroupJ M Jacobson, J S Greenspan, J Spritzler, et al.
Annals of Internal Medicine|December 4, 2001
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320L M Demeter, M D Hughes, R W Coombs, et al.
AIDS Research and Human Retroviruses|August 24, 2000
Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study TeamA Wiznia, K Stanley, P Krogstad, et al.
The Journal of Infectious Diseases|March 14, 1998
Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 TeamJ L Lathey, M D Hughes, S A Fiscus, et al.
AIDS (London, England)|April 10, 1999
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)P Musoke, L A Guay, D Bagenda, et al.
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|November 9, 2011
Phase behavior and properties of the liquid-crystal dimer 1'',7''-bis(4-cyanobiphenyl-4'-yl) heptane: a twist-bend nematic liquid crystalM Cestari, S Diez-Berart, D A Dunmur, et al.
The Journal of Infectious Diseases|June 3, 1999
Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials GroupJ M Jacobson, J Spritzler, L Fox, et al.
Pageof 24